Barclays Starts NVO, SNY at Overweight, GSK, AZN at Equalweight, NVS at Underweight
More News related to AZN
- AstraZeneca (AZN) Gets Additional Approval from U.S. FDA for CRESTOR
- US FDA Approves New Indication for CRESTOR(R) (rosuvastatin calcium)
- Atlantis(TM) Patient-Specific Abutment Now Available for NobelActive(TM) Implants
- AstraZeneca (AZN) Biz Unit MedImmune Announces Publication of Pivotal Trial for Motavizumab
- Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
More News related to GSK
- GlaxoSmithKline (GSK) to Close U.K. Research Center - DJN
- Nabi Biopharma (NABI) Receives $8M Milestone from Glaxo (GSK) Regarding PentaStaph Vaccine
- GlaxoSmithKline (GSK) Reports Q4 Adj-EPS of 34.4P, vs. Consensus of 33.5P
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
- Highlights From PFE's Q4 Conference Call: Wyeth Integration Going Well; Issues Guidance Through 2012
More News related to NVO
- Canaccord Adams Said Novo Approval Is Negative for Amylin (AMLN)
- Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
- Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
- Novo Nordisk (NVO) Announces FDA Approval of Victoza for Type 2 Diabetes
- Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
In the Healthcare sector, an analyst at Barclays has initiated coverage on several of the largest Major Drug stocks:
- Novo Nordisk (NYSE: NVO) with an Overweight
- Sanofi-Aventis (NYSE: SNY) with an Overweight and $56 price target
- GlaxoSmithKline (NYSE: GSK) with an Equalweight
- AstraZeneca (NYSE: AZN) with an Equalweight
- Novartis (NYSE: NVS) with an Underweight rating and a $48 price target
Related Categories
New CoverageStocks Mentioned
+0.98Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
